CMA Recommendations on Vaccine Equity and Intellectual Property
https://policybase.cma.ca/link/policy14476

POLICY TYPE  Parliamentary submission
DATE  2022-05-13
TOPICS  Ethics and medical professionalism
        Pharmaceuticals, prescribing, cannabis, drugs
        Population health, health equity, public health

Documents
Policy Brief: CSAM-SMCA in Support of the Decriminalization of Drug Use and Possession for Personal Use

https://policybase.cma.ca/link/policy14443

POLICY TYPE
Policy endorsement

DATE
2021-06-24

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs
Population health, health equity, public health
Taking action on drug shortages during Covid-19 – open letter
https://policybase.cma.ca/link/policy14261

POLICY TYPE  Parliamentary submission
DATE  2020-08-13
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs

Documents
Authorizing Cannabis for Medical Purposes

Policy document

LAST REVIEWED: 2020-02-29

DATE: 2015-02-28

TOPICS: Pharmaceuticals, prescribing, cannabis, drugs

Documents
Health Canada consultation on reducing youth access and appeal of vaping products
https://policybase.cma.ca/link/policy14078

POLICY TYPE  Response to consultation
DATE  2019-05-24
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs
Population health, health equity, public health

Documents
Cannabis for Medical Purposes

Policy document

LAST REVIEWED 2019-03-03
DATE 2010-12-04

Topics: Pharmaceuticals, prescribing, cannabis, drugs

Documents

CANNABIS FOR MEDICAL PURPOSES

Policy

CMA Policybase - Canadian Medical Association
MEDICATION USE AND SENIORS

(UPDATE 2017)

Drugs can potentially cause harm in seniors, and the potential is increased for those who are frail, physically or cognitively impaired, or institutionalized. The risks associated with polypharmacy are significant and include the following:

- Increased risk of adverse drug reactions
- Medication errors
- Difficulty managing medications
- Interactions with other drugs, alcohol, or substances
- Reduced capacity to engage in self-care
- Reduced ability to manage side effects
- Reduced ability to self-monitor

The use of multiple medications may pose additional risks in seniors, as follows:

- Increased risk of medication interactions
- Reduced ability to manage concurrent medications
- Reduced ability to self-monitor
- Increased risk of adverse drug reactions

While the Canadian Medical Association supports the development of a coordinated referral system to promote appropriate medication use in seniors, the need for such a system is not sufficient to prevent adverse drug events. However, the need to develop programs that help seniors manage their medications and improve their medication use can be achieved through the following strategies:

- Education and awareness
- Prescribing guidelines
- Medication management programs
- Medication review and monitoring
- Medication management support

These strategies can help seniors manage their medications effectively and reduce the risk of adverse drug events.
Vision for e-Prescribing: a joint statement by the Canadian Medical Association and the Canadian Pharmacists Association

https://policybase.cma.ca/link/policy10670

POLICY TYPE  Policy document
LAST REVIEWED  2019-03-03
DATE  2012-12-08
TOPICS  Health information and e-health
Pharmaceuticals, prescribing, cannabis, drugs

Documents
Health Canada consultation on Canadian drugs and substances strategy
https://policybase.cma.ca/link/policy14017

POLICY TYPE  Response to consultation
DATE  2018-12-04
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs
Population health, health equity, public health

Documents
Implementation of National Pharmacare

https://policybase.cma.ca/link/policy13933

POLICY TYPE  Response to consultation
DATE  2018-10-02
TOPICS  Health care and patient safety
Pharmaceuticals, prescribing, cannabis, drugs

Documents
Health Canada consultation on tobacco products regulations (plain and standardized appearance)
https://policybase.cma.ca/link/policy13930

POLICY TYPE: Response to consultation
DATE: 2018-09-06
TOPICS: Health care and patient safety
Pharmaceuticals, prescribing, cannabis, drugs

Documents
Support life-saving supervised consumption and overdose prevention sites: open letter to Premier Doug Ford and Health Minister Christine Elliott

https://policybase.cma.ca/link/policy13931

POLICY TYPE  Policy endorsement

DATE  2018-08-30

TOPICS  Pharmaceuticals, prescribing, cannabis, drugs

Documents
Health Canada consultation on regulatory amendments regarding tramadol
https://policybase.cma.ca/link/policy13927

<table>
<thead>
<tr>
<th>POLICY TYPE</th>
<th>Response to consultation</th>
</tr>
</thead>
<tbody>
<tr>
<td>DATE</td>
<td>2018-08-14</td>
</tr>
<tr>
<td>TOPICS</td>
<td>Pharmaceuticals, prescribing, cannabis, drugs</td>
</tr>
</tbody>
</table>

**Documents**
Health Canada consultation on restriction of marketing and advertising of opioids
https://policybase.cma.ca/link/policy13921

POLICY TYPE  Response to consultation
DATE  2018-07-18
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs

Documents
Consultation on proposed front-of-package labelling
https://policybase.cma.ca/link/policy13882

POLICY TYPE
Response to consultation

DATE
2018-04-23

TOPICS
Health care and patient safety
Pharmaceuticals, prescribing, cannabis, drugs

Documents
Bill C-45: The Cannabis Act
https://policybase.cma.ca/link/policy13861

POLICY TYPE: Parliamentary submission
DATE: 2018-04-18
TOPICS: Pharmaceuticals, prescribing, cannabis, drugs

Documents
CMA’s Recommendations for Bill S-5 An Act to amend the Tobacco Act and the Non-smokers’ Health Act and to make consequential amendments to other Acts
https://policybase.cma.ca/link/policy13918

POLICY TYPE  Parliamentary submission
DATE  2018-02-15
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs
Health care and patient safety

Documents
Proposed approach to the regulation of cannabis
https://policybase.cma.ca/link/policy13838

POLICY TYPE  Response to consultation
DATE  2018-01-19
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs

Documents